{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:12:03Z","timestamp":1785564723910,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:00:00Z","timestamp":1693699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:00:00Z","timestamp":1693699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The goal of therapy in essential thrombocythemia (ET) is reducing thrombotic risk. No algorithm to predict hemorrhage risk exists. The impact ofanti-platelet, cytoreductive and anticoagulation therapies on risk of major bleeding (MB) was evaluated. MB events were retrospectively analyzed in 1381 ET from 10 European centers. There were 0.286\u00a0MB events\/person-year. Neither the International Thrombosis Prognostic Score for thrombosis in essential thrombocythemia (IPSET-t) nor the revised IPSET-t (r-IPSET-t) was predictive for hemorrhage-free survival at 10\u00a0years (p\u2009=\u20090.092 vs p\u2009=\u20090.1). Ageand leukocyte count were MB risk factors, while low hemoglobin was protective. For ET with extreme thrombocytosis (ExtT) and leukocytosis cytoreduction was not protective. MB were more frequent in ET with ExtT who received anticoagulation. Antiplatelet therapy was not, while anticoagulation was a risk factor for MB (HR 3.05, p\u2009=\u20090.016, CI 1.23\u20137.56), in particular vitamin K antagonists (22.6% of those treated had a MB event, HR 2.96, p\u2009=\u20090.004, CI 1.41\u20136.22). Survival at 10\u00a0years was associated with hemorrhage (OR 2.54, p\u2009&lt;\u20090.001) but not thrombosis (HR 0.95, p\u2009=\u20090.829). Hemorrhage has a higher risk of mortality than thrombosis. Improved risk stratification for MB is necessary. The choice of anticoagulation, cytoreduction and antiplatelet therapies is an important area of research in ET.<\/jats:p>","DOI":"10.1007\/s12185-023-03650-7","type":"journal-article","created":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T07:01:11Z","timestamp":1693724471000},"page":"589-595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prediction of major bleeding events in 1381 patients with essential thrombocythemia"],"prefix":"10.1007","volume":"118","author":[{"given":"Ruth","family":"Stuckey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel M. Perez","family":"Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Soledad Noya","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Kulikowska","family":"de Na\u0142\u0119cz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Go\u0142os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Szukalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas M.","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0781-8668","authenticated-orcid":false,"given":"Marta Anna","family":"Sobas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,3]]},"reference":[{"issue":"26","key":"3650_CR1","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128\u201333.","journal-title":"Blood"},{"issue":"11","key":"3650_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5(11): e369.","journal-title":"Blood Cancer J"},{"issue":"6","key":"3650_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761\u201370.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3650_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057\u201369.","journal-title":"Leukemia"},{"issue":"10","key":"3650_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121(10):1720\u20138.","journal-title":"Blood"},{"issue":"1","key":"3650_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.18387","volume":"199","author":"R Stuckey","year":"2022","unstructured":"Stuckey R, Ianotto JC, Santoro M, et al. Validation of thrombotic risk factors in 1381 patients with essential thrombocythaemia: a multicentre retrospective real-life study. Br J Haematol. 2022;199(1):86\u201394.","journal-title":"Br J Haematol"},{"issue":"5","key":"3650_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1055\/s-0040-1720979","volume":"121","author":"C Nicol","year":"2021","unstructured":"Nicol C, Lacut K, Pan-Petesch B, Lippert E, Ianotto JC. Hemorrhage in essential thrombocythemia or polycythemia vera: epidemiology, location, risk factors, and lessons learned from the literature. Thromb Haemost. 2021;121(5):553\u201364.","journal-title":"Thromb Haemost"},{"issue":"4","key":"3650_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost"},{"key":"3650_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275\u201390.","journal-title":"Br J Haematol"},{"key":"3650_CR10","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26:716\u20139.","journal-title":"Leukemia"},{"key":"3650_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3650_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3892\/br.2016.727","volume":"5","author":"M Tomizawa","year":"2016","unstructured":"Tomizawa M, Shinozaki F, Hasegawa R, et al. Low hemoglobin levels are associated with upper gastrointestinal bleeding. Biomed Rep. 2016;5(3):349\u201352.","journal-title":"Biomed Rep"},{"issue":"07","key":"3650_CR13","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","volume":"120","author":"PJ Campbell","year":"2012","unstructured":"Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(07):1409\u201311.","journal-title":"Blood"},{"key":"3650_CR14","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","volume":"3","author":"A Carobbio","year":"2019","unstructured":"Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3:1729\u201337.","journal-title":"Blood Adv"},{"issue":"01","key":"3650_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3324\/haematol.2017.174672","volume":"103","author":"G Birgeg\u00e5rd","year":"2018","unstructured":"Birgeg\u00e5rd G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica. 2018;103(01):51\u201360.","journal-title":"Haematologica"},{"issue":"8","key":"3650_CR16","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3324\/haematol.2016.146654","volume":"101","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101(8):926\u201331.","journal-title":"Haematologica"},{"issue":"13","key":"3650_CR17","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/bloodadvances.2022007023","volume":"6","author":"N Gangat","year":"2022","unstructured":"Gangat N, Szuber N, Jadoon Y, et al. 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. Blood Adv. 2022;6(13):3835\u20139.","journal-title":"Blood Adv"},{"issue":"7","key":"3650_CR18","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood. 2006;108(7):2493\u20134.","journal-title":"Blood"},{"key":"3650_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","volume":"94","author":"N Szuber","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599\u2013610.","journal-title":"Mayo Clin Proc"},{"issue":"06","key":"3650_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","volume":"94","author":"JC Hern\u00e1ndez-Boluda","year":"2015","unstructured":"Hern\u00e1ndez-Boluda JC, Arellano-Rodrigo E, Cervantes F, et al. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol. 2015;94(06):911\u20138.","journal-title":"Ann Hematol"},{"issue":"1","key":"3650_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12657","volume":"6","author":"T Barbui","year":"2022","unstructured":"Barbui T, Carobbio A, De Stefano V. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost. 2022;6(1): e12657.","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"3650_CR22","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3324\/haematol.2021.279032","volume":"107","author":"JI Zwicker","year":"2022","unstructured":"Zwicker JI, Paranagama D, Lessen DS, et al. Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. Haematologica. 2022;107(5):1106\u201310.","journal-title":"Haematologica"},{"issue":"8","key":"3650_CR23","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3324\/haematol.2019.235994","volume":"105","author":"A Veninga","year":"2020","unstructured":"Veninga A, De Simone I, Heemskerk JWM, et al. Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica. 2020;105(8):2020\u201331.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03650-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T15:24:17Z","timestamp":1698679457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03650-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,3]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["3650"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03650-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,3]]},"assertion":[{"value":"27 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}